Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no important impairment on patient-reported quality of life. On the other hand, the landscape of EOC treatment is changing rapidly and poly (ADP-ribose) polymerase inhibitors (PARPi) currently play an important role in the management of EOC based on recent trials. At this point, an important question to be scrutinized is what to expect from up-front HIPEC in the era of amazing benefits by the PARPi. Herein, we discuss the promising role of combining PARPi and HIPEC in the management of advanced EOC.

Keywords

Injections / intraperitoneal / hyperthermia / induced / drug therapy / peritoneal neoplasms / surgical procedures / operative / poly (ADP-ribose) polymerases

References

[1] Vergote I,Chiva L.Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer..Cancer.2019;125 Suppl 24:4594-7

[2] Batista TP,Baiocchi G.How much “surgical eff ort” should be added to HIPEC?.Braz J Oncol2018;14:1-4

[3] Batista TP.Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study..Ann Surg Oncol2017;24:630

[4] van Driel WJ,Sikorska K,Schreuder HWR.Hyperthermic intraperitoneal chemotherapy in ovarian cancer..N Engl J Med2018;378:230-40

[5] Koole SN,Sikorska K,Schreuder HWR.Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer..Eur J Surg Oncol2019;

[6] Koole SN,van Driel WJ,Sikorska K.Cost effectiveness of interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer on the basis of a randomized phase III trial..J Clin Oncol2019;37:2041-205

[7] Passot G,Villeneuve L,Beaujard AC.What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures..J Surg Oncol2016;113:796-803

[8] Batista TP,Loureiro JF,Lopes A.A Proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and DMPM..Rev Col Bras Cir2017;44:530-44

[9] Spiliotis J,Lianos E,Grivas A.Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study..Ann Surg Oncol2015;22:1570-5

[10] Hettinga JV,Kampinga HH.Reduction of cellular cisplatin resistance by hyperthermia - a review..Int J Hyperthermia1997;13:439-57

[11] Bakrin N,Decullier E,Msika S.Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients..Eur J Surg Oncol2013;39:1435-43

[12] Pelz JO,Grimmig T,Moll E.Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia..Ann Surg Oncol2013;20:1105-13

[13] Zunino B,Villa E,Proics E.Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90..Oncogene2016;35:261-8

[14] Moore K,Scambia G,Oaknin A.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer..N Engl J Med2018;379:2495-505

[15] González-Martín A,Vergote I,Graybill W.Niraparib in patients with newly diagnosed advanced ovarian cancer..N Engl J Med2019;381:2391-402

[16] Coleman RL,Brady MF,Steffensen KD.Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer..N Engl J Med2019;381:2403-15 PMCID:PMC6941439

[17] Ray-Coquard I,Pignata S,González-Martín A.Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer..N Engl J Med2019;381:2416-28

[18] Gupta S,Aggarwal S,Warrier N.Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review..J Ovarian Res2019;12:103 PMCID:PMC6827246

[19] Piccart MJ,James K,Mangioni C.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results..J Natl Cancer Inst2000;92:699-708

[20] Ozols RF,Greer BE,Clarke-Pearson D.Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study..J Clin Oncol2003;21:3194-200

[21] Armstrong DK.Role of intraperitoneal therapy in the initial management of ovarian cancer..J Clin Oncol2019;37:2416-9

[22] Riggs MJ,Kim J.Hyperthermic intraperitoneal chemotherapy in ovarian cancer..Diagnostics (Basel)2020;10:43 PMCID:PMC7168334

[23] Basourakos SP,Aparicio AM,Kim J.Combination platinum-based and DNA damage response-targeting cancer therapy: evolution and future directions..Curr Med Chem2017;24:1586-606 PMCID:PMC5471128

[24] Lesnock JL,Tian C,Thrall MM.BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study..Br J Cancer2013;108:1231-7 PMCID:PMC3619264

[25] Naumann RW,Tait DL,Crane EK.Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer..Gynecol Oncol2018;151:477-80

[26] Safra T,Inbar M,Dayan D.Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study..J Surg Oncol2014;110:661-5

[27] Yarema R,Fetsych T,Petronchak O.Cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy) in combined treatment of ovarian cancer: time for the beginning of personalized therapy?.Curr Issues Pharm Med Sci2019;32:154-9

[28] Heitz F,Åvall-Lundqvist E,Pautier P.Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12..Gynecol Oncol2019;152:2

[29] Deraco M,Salcedo-Hernández RA,Baratti D.Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy..Eur J Surg Oncol2019;45:2103-8

[30] Somashekar S,Ashwin K,Ahuja VK.334 A prospective non-randomized study comparing the outcomes following complete versus selective parietal peritonectomy during CRS+HIPEC for advanced epithelial ovarian cancer..Int J Gynecol Cancer2019;29:A138

[31] Tate S,Kato K,Kambe M.Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer..J Gynecol Oncol2020;31:e34 PMCID:PMC7189082

[32] da Costa AA,Baiocchi G,Saito A.Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer..Ann Surg Oncol.2015;22 Suppl 3:S971-8

[33] Cecere SC,Salutari V,Lorusso D.Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome..Gynecol Oncol2020;156:38-44

[34] Krawczyk PM,Essers J,Rodermond H.Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition..Proc Natl Acad Sci U S A2011;108:9851-6 PMCID:PMC3116433

[35] Hegyi G,Szász A.Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy..Evid Based Complement Alternat Med2013;2013:672873 PMCID:PMC3638606

[36] Schaaf L,Ulmer C,Mürdter TE.Hyperthermia synergizes with chemotherapy by inhibiting PARP1-dependent DNA replication arrest..Cancer Res2016;76:2868-75

[37] Batista TP.Comments on: pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study..J Gynecol Oncol2019;30:e111 PMCID:PMC6779613

[38] Batista TP,Tancredi R,Badiglian-Filho L.Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach..Cancer Manag Res2017;9:869-78 PMCID:PMC5732565

[39] Neuenschwander B,Hollaender N,Branson M.A proof of concept phase II non-inferiority criterion..Stat Med2011;30:1618-27

[40] Paoletti X,Daniele G,Yanaihara N.Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis..JAMA Netw Open2020;3:e1918939 PMCID:PMC6991254

[41] Yarema R,Volodko N,Petronchak O.Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: two pathogenetic types based study..J Surg Oncol2018;117:1806-12